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erative period.2 However, recent innovations in thera-
pies have had a positive effect. Nonetheless, a molecu-
lar strategy may provide an important form of ventricu-
lar support in the setting of acute graft dysfunction.
β-Adrenergic receptor (β-AR) signaling abnormali-
ties have been well described in native heart failure3,4;
however, β-AR signaling in transplanted myocardium
V entricular dysfunction after heart transplantation isan attractive target for cardiac gene therapy. There
are multiple causes of graft dysfunction, including
preservation injury, rejection, and pulmonary hyperten-
sion.1 Current therapeutic approaches center on phar-
macologic and mechanical support that historically
have been associated with poor outcomes in the periop-
Objectives: Ex vivo perfusion of the cardiac allograft during organ procure-
ment is an ideal environment for adenoviral vectors with transgenes that tar-
get improving graft contractility. One such target is the β-adrenergic recep-
tor–signaling system, in which alterations in transgenic mice have elucidated
novel means to improve the function of the heart in vivo. The purpose of the
current study was to determine the functional consequences of β-adrenergic
receptor manipulation in a rabbit model of cardiac allograft transplantation.
Methods: New Zealand White rabbits weighing 3 kg served as recipients to
1-kg outbred donors. Donor hearts were arrested and harvested, and 1 of 3
adenoviral constructs was administered into the aortic root perfusing the
graft. Transgenes delivered encoded either the human β2-adrenergic receptor,
a peptide inhibitor of β-adrenergic receptor densensitization, or the marker
transgene β-galactosidase.
Results: Five days after cervical heterotopic transplantation, left ventricular
performance was measured on a Langendorff apparatus. A moderate pattern
of rejection was seen in all grafts. Biventricular myocyte expression of 
β-galactosidase was observed, and β2-adrenergic receptor density was ele-
vated 10-fold in grafts that received adeno-β2-adrenergic receptor. Left ven-
tricular systolic and diastolic performance was significantly increased in
grafts transfected with either adeno-β2-adrenergic receptor or adeno-β-
adrenergic receptor densensitization compared with control grafts that
received adeno-β-galactosidase.
Conclusions: Ex vivo adenovirus-mediated gene transfer is feasible in a rab-
bit allograft model and, more important, genetic manipulation of β-adrener-
gic receptor signaling either by increasing β2-adrenergic receptor density or
blocking endogenous receptor desensitization improves graft function acute-
ly in this allograft model. (J Thorac Cardiovasc Surg 2000;120:581-8)
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has not been clearly understood to date. Evidence exists
for upregulation of β2-ARs, whereas β1-ARs downreg-
ulate, and receptors are uncoupled in grafts undergoing
acute rejection.5-8 Therefore, transplanted myocardium
appears to recapitulate, at least in part, the β-AR sig-
naling abnormalities associated with heart failure,
despite its unique physiology. Accordingly, a therapeu-
tic strategy to enhance β-AR signaling may provide an
intrinsic form of ventricular support for the grafted
heart. This approach includes enhancement of β-AR
signaling through overexpression of the β2-AR or
inhibiting desensitization. To inhibit β-AR desensitiza-
tion, our laboratory has developed and used an inhibitor
of β-adrenergic receptor kinase 1 (β-ARK1), the β-
ARKct, which is a 194-amino acid peptide that com-
petes with β-ARK1 for binding to the βγ-subunit of
activated heterotrimeric G proteins (Gβγ), a process
required for β-ARK1 activation.9,10 Interestingly, in
transgenic mice myocardium-targeted overexpression
of β2-ARs at greater than 100-fold over endogenous
levels11 or the β-ARKct10 resulted in significantly
enhanced in vivo cardiac function without significant
pathology,12 whereas 10-fold overexpression of the β1-
AR in the hearts of transgenic mice leads to early
hypertrophy and cardiomyopathy.13 Thus, the β2-AR
appears to offer a therapeutic advantage over the β1-
AR.12 Furthermore, β-AR signaling abnormalities pre-
sent in isolated failing cardiomyocytes have been res-
cued by adenovirus-mediated overexpression of the
β2-AR or the β-ARKct.14
Previous work in our laboratory and others has demon-
strated the feasibility of transgene delivery by using ade-
noviral vectors to grafts during harvesting and implanta-
tion.15-18 Work by Brauner and colleagues19 and Qin and
associates20 has also demonstrated the possibility of
immune modulation by using immunosuppressant trans-
genes, such as tumor growth factor β and interleukin 10.
The focus of the current study was to examine the func-
tional consequences of adenovirus-mediated gene trans-
fer of transgenes that enhance β-AR signaling. Po-
tentially, this could lead to improved cardiac allograft
contractility that could favorably go hand in hand with
genetic manipulation of immune properties of the graft to
improve cardiac dysfunction seen perioperatively and
during acute rejection episodes.
Methods
Adenoviral constructs. Adenoviral constructs with a first-
generation, E1/E3-deleted, replication-deficient adenovirus
have previously been described. The β2-AR (adeno-β2AR), β-
ARKct (adeno-β-ARKct), and marker transgene β-galactosi-
dase (adeno-βGal) were driven by the cytomegalovirus pro-
moter. Large-scale preparations of these adenoviruses were
purified from transfected 293 cells, as previously
described.14,15
Animal preparation.  Male New Zealand White rabbits (3
kg) served as recipients to 1-kg donors and were obtained
from separate vendors. All procedures were humanely per-
formed in accordance with the regulations adopted by the
National Institutes of Health and approved by the Animal
Care and Use Committee of Duke University. Each animal
was sedated with ketamine (80 mg/kg) and acepromazine
maleate (INN: acepromazine; 0.25 mg/kg). The recipient was
then shaved and prepared in a sterile fashion over the right
side of the neck, and an incision was made with 1% lidocaine.
The internal carotid and external jugular veins were then dis-
sected, and 500 U of heparin was given to the recipient.
Attention was then turned to the donor. After endotracheal
intubation and ventilation, the heart was exposed by means of
a clamshell incision. Three thousand units of heparin was
then administered into the inferior vena cava, and it was lig-
ated with 3-0 silk suture. The aorta and pulmonary artery
were then dissected, and a clamp was placed across the aorta.
Fifteen milliliters of University of Wisconsin solution was
then delivered into the aortic root, and the great vessels were
transected. The remaining vessels were ligated en bloc, and
the heart was placed in saline solution at 4°C. Total viral par-
ticles (1 × 1010) in a total saline volume of 1.0 mL of a repli-
cation-deficient adenovirus containing adeno-β-ARKct 
(n = 12), adeno-β-Gal (n = 8), adeno-β2-AR (n = 10), or
saline solution (n = 4) were then injected into the aortic root
and through the coronary arteries. The graft was then anasta-
mosed to the recipient vessels with 7-0 Prolene sutures
(Ethicon, Inc, Somerville, NJ). The donor aorta was anasta-
mosed end to side to the carotid artery, and the donor pul-
monary artery was anastomosed to the jugular vein.19,21
Grafts were then reperfused and resumed vigorous contrac-
tion within 5 minutes. Total ischemic time was approximate-
ly 50 minutes for all grafts. All grafts were palpated daily.
Functional assessment. On postoperative day 5, grafts
were excised and placed on a modified Langendorff appa-
ratus for measurement of left ventricular (LV) function.16,22
A balloon was placed into the left ventricle through the left
atrium, inflated to 8 to 10 mm Hg, and connected to a
micromanometer to measure intracavitary pressure. The
coronary perfusion flow was maintained at 20 mL/min at
35°C. Oxygenated modified Krebs-Henseleit solution was
used as the perfusate.16 After 30 minutes of equilibration,
LV intracavitary pressure was recorded on a personal com-
puter–based acquisition system at 200 Hz (Physiologic
Systems, Durham, NC) while being paced at 215
beats/min. After acquisition of baseline data, epinephrine
(10–7 mol/L) was infused, and the maximal response was
measured. After data acquisition, transmural samples of the
left and right ventricles were then frozen in liquid nitrogen
for biochemical analysis. The maximal rate of LV pressure
rise (dP/dt
max
) was used as a measure of contractile func-
tion and derived from the average of 20 steady-state beats.
The minimum (dP/dt
min) was used as a measure of global
ventricular relaxation.
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Determination of myocardial β-AR density. β-AR
binding was performed from purified myocardial sarcolem-
mal membranes, as previously described.10,11 Final mem-
branes were resuspended at 1 to 2 mg/mL, and total β-AR
density was determined by incubating 25 µg of sarcolemmal
membranes with a saturating concentration (300 pmol/L) of
[125I]-cyanopindolol and 20 µmol/L alprenolol to define
nonspecific binding.10,11
Protein immunoblotting. Protein immunoblotting to
detect the presence of the β-ARKct was performed, as previ-
ously described, by using polyclonal antiserum raised to the
carboxyl terminus of β-ARK1.14 Immunodetection of
myocardial levels of β-ARK1 was performed on equal
amounts of protein from cytosolic extracts after immunopre-
cipitation by means of a monoclonal β-ARK1 antibody.14
Histologic and β-Gal staining. After excision, transverse
cross sections of myocardium at the midpapillary level were
obtained for histologic analysis and stored in 30% sucrose
solution before paraffin embedding, as previously de-
scribed.15,16 Paraffin-embedded samples were mounted on a
cryostat and sectioned into 5- to 10-µm thin sections, which
were then transferred to a glass slide. β-Gal staining was per-
formed in 5 mmol/L ferrocyanide, 5 mmol/L ferriccyanide, 2
mmol/L MgCl2, 0.02% Igepal CA-630 (Sigma Chemical Co,
St Louis, Mo), 0.01% sodium deoxycholate, 5 mmol/L ethyl-
eneglycol-bis-(β-aminoethylether)-N,N,N´,N´-tetraacetic acid,
and 1 mg/mL X-Gal in Tris-buffered saline solution (pH 7.5) at
37°C for up to 24 hours. Hematoxylin and eosin staining was
performed on all samples by using standard techniques.15,16
Data analysis.  All summary data are expressed as the
mean ± SEM. All comparisons were performed by a 1-way
analysis of variance. Pairwise comparisons were then made
with a Bonferroni t test.
Results
Adenovirus-mediated expression of transgenes.
Ex vivo delivery of adenoviral constructs resulted in
biventricular expression of the respective transgenes. In
grafts perfused with adeno-β-Gal, global expression of
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Fig 1. Representative histologic specimens of rabbit cardiac allografts treated with adeno-β-Gal. A, Whole mount
(low-power) section of a heart 5 days after the ex vivo delivery of 1 × 1010 total viral particles of adeno-β-Gal and
heterotopic transplantation. Global and robust myocardial expression of β-Gal is evident. B, A higher power view
demonstrating that the β-Gal transgene is expressed in individual myocytes. C, Hematoxylin and eosin–stained sec-
tion from the right ventricle of a saline-treated allograft 5 days after transplantation with evidence of infiltrating
inflammatory cells, indicating a moderate pattern of rejection in this transplanted heart.
A B
C
the transgene was seen throughout the myocardium
(Fig 1, A). High-power views confirm the staining of
individual myocytes and not inflammatory cells (Fig 1,
B). Importantly, donor and recipient animals were from
different colonies, and thus a pattern of moderate rejec-
tion, as evidenced by inflammatory cell infiltrates, was
seen in hearts 5 days after transplantation (Fig 1, C),
making this an allograft model.
In grafts that received adeno-β2-AR, marked overex-
pression of the β2-AR was observed throughout the
myocardium, with over a 10-fold increase in β-AR den-
sity compared with nontransplanted myocardium (Fig
2, A). Significant overexpression of the β2-AR was seen
in the left ventricle, right ventricle, and septum, con-
firming an intracoronary delivery of adenoviral vectors
previously illustrated above by the X-Gal staining. β-
AR density was also performed on grafts that received
adeno-β-ARKct and adeno-β-Gal. No significant alter-
ation of β-AR density was observed in adeno-β-
ARKct– and adeno-β-Gal–transfected grafts versus
normal myocardium (Fig 2, B). This importantly
demonstrates that donor hearts from nonisogenic
strains do not have endogenously higher β-AR density,
and the increased density seen in the adeno-β2-
AR–treated grafts is caused by transgene expression. In
addition, expression of adenoviral transgenes was not
found in any organ or tissue of the recipient animal out-
side of the donor heart (data not shown). Protein
immunoblotting was performed to detect the presence
of the β-ARKct peptide. The presence of this peptide
inhibitor of β-ARK1 activity was seen globally in
grafts that received adeno-β-ARKct (Fig 3), but the 30-
kd β-ARKct was not detected in the recipient’s native
myocardium (data not shown) or liver.
Functional consequence of transgene expression
on LV contractile performance. The functional con-
sequence of graft-specific β-AR transgene expression
was evaluated on an isolated Langendorff apparatus.
The maximal first derivative of intracavitary pressure
(dP/dt
max
) was used as a measure of global LV contrac-
tile performance 5 days after transgene delivery. Grafts
that received either adeno-β2-AR or adeno-β-ARKct
had a significant improvement in systolic ventricular
function compared with adeno-β-Gal control grafts
(Fig 4). The significant improvement in baseline func-
tion was similar in the hearts that received the 2 func-
tional transgenes with increases of 129% and 123%,
respectively, from adeno-β-Gal–treated hearts (Fig 4,
A; P < .05). Epinephrine was used to further character-
ize LV contractile function after transgene delivery.
The LV dP/dt
max
response to epinephrine was marked-
ly increased in adeno-β2-AR and adeno-β-ARKct
grafts compared with adeno-β-Gal–treated hearts (Fig
4, B). Interestingly, hearts expressing β-ARKct had a
greater increase in LV systolic performance in response
to epinephrine compared with the increase found in β2-
AR–overexpressing transplanted hearts (Fig 4, B). We
chose to measure function at 5 days after gene delivery
because of our previous study in transplanted rat heart
isografts that demonstrated that peak transgene expres-
sion was between 5 to 7 days, and by day 14, most of
the transgene expression was absent, which is typical
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Fig 2.  β-AR density in allografted hearts after ex vivo adenovirus-mediated gene delivery. A, Total β-AR density
in grafts that received adeno-β2-AR (n = 10). A 10-fold overexpression was seen in grafts in both ventricles. 
*P < .001 versus native cardiac β-AR density. B, Total β-AR density in the left ventricle of all treated groups.
Treatment of allografts with adeno-β-ARKct (n = 12) or adeno-β-Gal (n = 8) did not significantly alter myocardial
β-AR density compared with native myocardium (n = 6). *P < .001 versus adeno-β-ARKct, adeno-β-Gal, and
native left ventricle. LV, Left ventricle; RV, right ventricle.
A B
of these types of adenovirus vectors.16 However, we did
not measure the duration of transgene expression in
this rabbit allograft model.
Using LV dP/dt
min as a measure of cardiac relaxation,
a significant improvement in lusitropy was seen in
adeno-β-ARKct– and adeno-β2-AR–transfected grafts
compared with the diastolic function seen in control
allografts that received adeno-β-Gal. No significant
difference in relaxation was observed between adeno-
β-ARKct or adeno-β2-AR grafts (Fig 5, A). Further-
more, ephinephrine-stimulated relaxation was signifi-
cantly improved in grafts that received either of the 2
functional transgenes compared with adeno-β-
Gal–treated control grafts (Fig 5, B). Importantly, β-
ARKct and β2-AR overexpression resulted in a similar
enhancement of agonist-mediated dP/dt
min responses.
Discussion
The major findings of the present study are 2-fold.
First, this study expands the application of acquired
transgenesis to the field of cardiac allograft transplan-
tation and provides novel therapeutic targets to improve
the functional performance of the donor heart. Previous
reports in this area have concentrated on immunomod-
ulation.19,20 Specifically, this study is unique in that it
uses a rabbit allograft heterotopic heart transplant
model to demonstrate that enhanced β-AR signaling,
either through increased receptor density or inhibiting
desensitization, leads to enhanced function of the graft,
even in the face of mild-to-moderate rejection and
ischemic injury. A second novel aspect of this study is
that it represents the first report, outside transgenic
mice, demonstrating that the β-ARKct and subsequent
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Fig 3. β-ARKct expression in allografted hearts after ex vivo adeno-β-ARKct delivery. Representative protein
immunoblot of an allograft treated with adeno-β-ARKct. Presence of the approximately 30-kd protein β-ARKct
was confirmed in both chambers of the heart and absent in the recipient’s liver. In addition, there was no detectable
β-ARKct expression in the recipient’s heart (data not shown). RV, Right ventricle; LV, left ventricle.
Fig 4. LV dP/dt
max
, as a measure of cardiac contractile function, assessed on isolated allografts 5 days after gene
delivery and heterotopic transplantation. A, dP/dt
max
was significantly increased at baseline in grafts treated with
adeno-β2-AR (n = 10) or adeno-β-ARKct (n = 12) compared with values in adeno-β-Gal–treated grafts (n = 8). *P
< .001. B, LV dP/dt
max
responses to epinephrine (10–7 mol/L). Adeno-β2-AR– and adeno-β-ARKct–treated grafts
exhibited significant improvement in systolic function over adeno-β-Gal–treated hearts, and adeno-β-ARKct–
treated hearts had a greater response to epinephrine compared with adeno-β2-AR treatment. *P = .006 versus
adeno-β-Gal. †P = .04 versus adeno-β2-AR.
A B
inhibition of myocardial β-ARK1 activity leads to
enhanced global cardiac contractility and relaxation.
More important, this has taken place acutely after ade-
novirus-mediated gene delivery in a larger animal
model that differs considerably from constitutive over-
expression in transgenic mice.
The perioperative period after cardiac transplantation
is a particularly tenuous time. Ischemia, as well as
autonomic dysfunction in the brain-dead donor, can
also affect ventricular function, probably as a result of
β-AR desensitization.23,24 After graft implantation, the
right ventricle is subjected to elevated afterload and
may fail, causing further hemodynamic instability.
These physiologic factors are further complicated by
the fact that the transplanted heart is denervated and
catecholamine dependent. All of these diverse variables
affect and impinge on overall graft function, particular-
ly in the perioperative period, and ultimately affect
patient outcome. Thus, preserving the functional
integrity of the grafted heart is an important goal that
could also expand the use of marginal grafts that may
be rescued with gene therapy.
Thirty years of research in preservation solutions has
illustrated that metabolic manipulation of the graft dur-
ing procurement is feasible. Recent work by our group
and others has extended this concept to genetic manip-
ulation. The cold, arrested, ischemic heart is an ideal
milieu for gene transfer. First, ex vivo perfusion allows
graft-limited contact with adenoviral vectors. Second,
the transport and preservation time allows for sustained
contact time and robust overexpression of transgenes at
much lower viral titers than is needed for in vivo trans-
fection. Thus in this rabbit allograft model we can
directly test whether genetic manipulation of the
myocardial β-AR system can lead to improved function
perioperatively.
Overexpression of either β2-ARs or blocking β-
ARK1 in transgenic mouse models, studies in isolated
cardiomyocytes, or both has been shown to reverse the
changes seen in heart failure, as well as improving con-
tractility in normal myocardium.10,11,14,25 These studies
done in our laboratory form the basis of our current
gene therapy strategy in transplanted myocardium. The
present study is unique in that it uses a rejecting model
of myocardium and attempts to improve function in
this setting of graft dysfunction. Not only does this
model incorporate immunologic injury, but there are
elements of ischemic, as well as preservation and re-
perfusion, injury. Although none of these factors were
individually identified, they all conspire in the early
graft period, even in experimental transplantation. Of
these factors, only ventricular loading is not present in
commonly used heterotopic transplant models.
Part of the utility of β-AR manipulation in cardiac
transplantation rests in the fact that signaling is altered
in the perioperative period. It is increasingly clear that
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Fig 5. LV dP/dt
min, as a measure of cardiac relaxation assessed on isolated allografts 5 days after gene delivery and
heterotopic transplantation. A, Both adeno-β-ARKct–transfected (n = 12) and adeno-β2-AR–transfected (n = 10)
grafts showed marked improvement in baseline relaxation compared with adeno-β-Gal–treated control grafts 
(n = 8). No significant difference in dP/dt
min was observed between adeno-β-ARKct and adeno-β2-AR. 
B, Epinephrine (10–7 mol/L) stimulated relaxation. LV dP/dt
min response was significantly greater in adeno-β2-AR–
and adeno-β-ARKct–treated animals compared with adeno-β-Gal treatment. *P < .001 versus adeno-β-Gal for both
adeno-β-ARKct and adeno-β2-AR.
A B
β-ARK1 is a critical regulator of myocardial function.
Increased myocardial expression of β-ARK1 has been
found to be associated with ventricular dysfunction in
myocardial hypertrophy,26 ischemia,27 and human con-
gestive heart failure.28 In addition, β-ARK1 upregula-
tion has been implicated in human hypertension.29
Transgenic mice with increased β-ARK1 expression
targeted to the heart were found to have β-AR receptor
uncoupling and ventricular dysfunction after β-agonist
administration.10 Actual uncoupling from second mes-
senger systems in cardiac allografts, however, has been
difficult to prove. Experimental evidence exists for a
decline in adenylyl cyclase activity,7 but no clinical
data exist in human transplantation.5 In several studies
acute rejection was associated with a downregulation
of total β-AR density, recapitulating changes seen in
heart failure.3,8,30 Interestingly, we have found that β-
ARK1 expression was elevated in our rabbit allografts
(data not shown), and thus β-ARK1 upregulation may
be responsible for some of the observed signaling
abnormalities seen in both experimental and clinically
transplanted hearts.
The current study demonstrates that adenovirus-
mediated delivery of transgenes to the transplanted
heart is feasible through ex vivo perfusion and can
improve contractile function. First, overexpression of
β2-ARs significantly improved contractile function 5
days after transplantation in this model both basally
and in response to a β-agonist. Previous studies in
transgenic mice have demonstrated that β2-AR overex-
pression improves contractile function through
improved coupling to second messenger systems and
cyclic adenosine monophosphate production.11
Furthermore, acquired overexpression of β2-ARs,
either by ex vivo or in vivo adenovirus-mediated gene
delivery to rat and rabbit hearts, has been found to
improve normal and isografted myocardium.14,31
Because our rabbit model of transplantation involves a
level of rejection, data from this study importantly pro-
vide evidence that β2-AR overexpression can improve
systolic and diastolic performance in the dysfunctional
myocardium.
In this study the ex vivo delivery and expression of β-
ARKct in grafts improved baseline LV contractile per-
formance to the same extent as β2-AR overexpression.
Interestingly, although both transgenes were able to
improve baseline systolic and diastolic performance,
adeno-β-ARKct–treated cardiac allografts also exhibit-
ed a significant increase in inotropic response to a β-
agonist over the improvement seen with β2-AR overex-
pression. This improved β-AR responsiveness after
β-ARKct expression may indicate that enhanced sig-
naling through endogenous β-ARs (primarily β1-ARs)
is a more powerful means to improve the performance
of the heart than overexpressing the β2-AR. Thus β-
ARK1 inhibition with the β-ARKct might be advanta-
geous over β2-AR overexpression. This may have pro-
found implications and utility in transplantation. The
transplanted heart is catecholamine dependent because
it is denervated and, as such, safely improving inotrop-
ic responsiveness may further enhance in vivo function
where circulating catecholamines play a role in base-
line function. This study is among the first to compare
the functional consequences of these 2 transgenes in a
model of acquired transgenesis.
In summary, the results of this study demonstrate that
altering β-AR signaling is an appealing target for car-
diac gene therapy and provides a novel treatment strat-
egy for ventricular dysfunction. Gene therapy to
improve cardiac function in the setting of transplanta-
tion may provide substantial clinical benefit. The cur-
rent study examined the functional consequences of 2
transgenes that alter β-AR signaling in different ways.
They both significantly increased contractility in this
model of cardiac allotransplantation. Future work will
concentrate on using these powerful transgenes in larg-
er loaded models of cardiac transplantation.
We thank Kyle Shotwell and Kurt Campbell for their excel-
lent technical assistant and the Genzyme Corporation
(Framingham, Mass) for preparation and purification of some
of the adeno-β2-AR and adeno-β-ARKct.
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